It's kill and cure in pharma sales

July 2003
Marketing Week;7/17/2003, Vol. 26 Issue 29, p16
Trade Publication
Comments on the marketing strategy used by Biovail Corp., which sells anti-hypertension products during a cardiology conference in Great Britain.


Related Articles

  • Biovail reports record 1999 4th qtr/year-end results.  // Biotech Financial Reports;Apr2000, p2 

    Reports that Toronto, Ontario-based biotechnology company Biovail Corp. International has announced record earnings during the fourth quarter of 1999. Percentage increase in the company's earnings during the fourth quarter of 1999 as compared to that of the same period in 1998; Net income and...

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/11/2009, Vol. 20 Issue 111, p6 

    This section offers news briefs concerning finance in the biotechnology sector as of June 2009. A three-year $410 million revolving credit facility was obtained by Biovail Corp. from a syndicate of banks. The senior secured convertible notes of Generex Biotechnology Corp. issued in March 2008 to...

  • Biovail files NDA for novel dosage form of anti-depressant.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12 

    Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.

  • The competitive advantage of early and rapidly internationalising SMEs in the biotechnology industry: A knowledge-based view. Gassmann, Oliver; Keupp, Marcus Matthias // Journal of World Business;Sep2007, Vol. 42 Issue 3, p350 

    Abstract: Our knowledge on �born globals� (BG) is fragmented and lacks an integrative framework. Starting from a knowledge-based view of the firm, we analyse internationally active biotechnology small and medium enterprises (SMEs) from Switzerland, Germany, and Australia to find out...

  • Sudden impact. Coten, Ned; Szabo, Alexander; Hyde, Becky // Australasian Biotechnology;Oct2011, Vol. 21 Issue 3, p39 

    First impressions are lasting impressions -- this adage applies just as well to biotech companies as it does to individuals. Despite this, many Australian biotech companies don't invest sufficient effort in developing their public impression -- their BRAND -- to do justice to the value of their...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/14/2008, Vol. 19 Issue 72, p3 

    This section offers news briefs on the biotechnology industry. David J. Masso has resigned as president, CEO, and as a member of the board of directors of AEterna Zentaris Inc. Eugene Melnyk, former chairman and CEO of Biovail Corp., has withdrawn an application to the Ontario Supreme Court of...

  • OTHER NEWS TO NOTE.  // BioWorld Today;5/19/2008, Vol. 19 Issue 97, p2 

    This section offers news briefs related to the biotechnology industry. The U.S. Food and Drug Administration has accepted Arpida Ltd.'s iclaprim, an intravenous drug application for complicated skin and skin structure infections. Biovail Corp. has decided to settle charges against it by the U.S....

  • COMPANY SPOTLIGHT-- Amgen.  // PharmaWatch: Biotechnology;Jun2005, Vol. 4 Issue 6, p24 

    The article presents a corporate profile for Amgen Inc., a leading biotechnology company that specializes in molecular and cellular biology. The company offers human therapeutic products in areas such as nephrology, supportive cancer care and inflammatory disease. Principal products include...

  • Counterpoint: biotech needs more than DTC as usual. Mack, John // Nature Biotechnology;Mar2006, Vol. 24 Issue 3, p267 

    The article focuses on the counter arguments of the pharmaceutical marketing expert regarding the adoption of direct-to-consumer (DTC) advertising of biotechnological industry in the U.S. He argued that what was good for pharmaceutical industry may not necessarily applicable in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics